Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period

Haematologica

Volumn 97, Issue 3, 2012, Pages 459-463

  Ananda Rajah, Michelle R ^a   Grigg, Andrew ^b   Downey, Maria T ^b   Bajel, Ashish ^b   Spelman, Tim ^c,d   Cheng, Allen ^a,e   Thursky, Karin T ^b,f   Vincent, Janette ^b   Slavin, Monica A ^b,f  

^a Infectious Diseases Unit   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Acute myeloid leukemia; Fungal infections; Posaconazole; Prophylaxis; Voriconazole

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIVER TOXICITY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; FEMALE; FLUCONAZOLE; HUMANS; ITRACONAZOLE; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84857733187     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051995     Document Type: Article

References (23)

1. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95(4):644-50.
2. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21(2):361-9.
3. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Pro-spective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009; 48(3):265-73.
4. Perkhofer S, Lass-Florl C, Hell M, Russ G, Krause R, Honigl M, et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents. 2010;36(6):531-6.
5. Even C, Bastuji-Garin S, Hicheri Y, Pautas C, Botterel F, Maury S, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived to fungal disease. A case-control study. Haema-tologica. 2010;96(2):337-41.
6. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-59.
7. Ananda-Rajah MR, Cheng A, Morrissey CO, Spelman T, Dooley M, Neville AM, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55(5):1953-60.
8. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis--has the principle been proven? N Engl J Med. 2007;356(4):409-11.
9. Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol. 2008;81(3):242-3.
10. Vehreschild JJ, Ruping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466-77.
11. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21.
12. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard, 2nd 144 ed. M38-A2. Clinical and Laboratory 145 Standards Institute, Wayne, PA 2008.
13. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009; 53(1):24-34.
14. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A metaanalysis of 16 randomized, controlled trials. Cancer. 2000;89(7):1611-25.
15. Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis. 2008;46(10):1626-7; author reply 7-8.
16. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068-75.
17. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624-33.
18. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother. 2010;65(3):410-6.
19. Eiden C, Peyriere H, Cociglio M, Djezzar S, Hansel S, Blayac JP, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother. 2007;41(5):755-63.
20. Riedel A, Choe L, Inciardi J, Yuen C, Martin T, Guglielmo BJ. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis. 2007;7:70.
21. Alanio A, Sitterle E, Liance M, Farrugia C, Foulet F, Botterel F, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011;66(2):371-4.
22. Lewis G, Hall P, Eisa N, Deremer D, Dobbins R, El-Geneidy M, et al. Acute Myelogenous Leukemia Patients Are at Low Risk for Invasive Fungal Infections after High-Dose Cytarabine Consolidations and Thus Do Not Require Prophylaxis. Acta Haematol. 2010;124(4):206-13.
23. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for highrisk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042-51.